Bharat Biotech announces results of third phase trial of COVAXIN, 81% effective

New delhi date. Wednesday, March 3, 2021

Bharat Biotech on Wednesday released data on the third phase of clinical trials of indigenous corona vaccine covexin. Covexin proved to be 81 percent effective in the third phase of the trial, according to the company. It is pertinent to mention that the cove vaccine was raised with the approval of the government for emergency use. The reason was that Covexin was still in its third phase of trial when it was approved and its data were not even released.

Now Bharat Biotech has put an end to all the questions by releasing the data of the third phase trial. It is worth mentioning that covacin is also being used for coronary vaccination in the country. Currently, Prime Minister Narendra Modi has also taken the first dose of covacin vaccine.

Bharat Baytech said the data became available after a trial of 25,800 people. Within which the vaccine is proportional to its effectiveness. The vaccine was tested in conjunction with ICMR. The company says that the second dose of the vaccine has been shown to have a positive effect on people. The results of all these trials have shown that the vaccine is 81% effective in preventing coronavirus.

The vaccine is also effective against new strains of the corona virus. India Biotech said that so far 40 countries around the world have shown interest in taking covacin.